AIP
SGTX

Ameritas Investment Partners’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Ameritas Investment Partners’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-48
Closed -$1K – 3329
2022
Q1 		$1K Hold
48
– – ﹤0.01% 3077
2021
Q4 		$2K Hold
48
– – ﹤0.01% 3098
2021
Q3 		$4K Hold
48
– – ﹤0.01% 3057
2021
Q2 		$7K Hold
48
– – ﹤0.01% 2976
2021
Q1 		$14K Buy
+48
New +$19.1K ﹤0.01% 2728

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameritas Investment Partners's SGTX Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 48 shares — an estimated $1K sold.

Ameritas Investment Partners first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $14K in Q1 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 48 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1K.
  • Ameritas Investment Partners first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Ameritas Investment Partners's Sigilon Therapeutics, Inc. Common Stock position peaked at $14K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.